List of Digital Health/Medicine Companies in California - 18

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Biotricity is a global frontrunner in the realm of digital health. Our mission is to bridge the gap between patients and healthcare providers, ushering in a new era of care delivery that is both efficient and patient-centric. At Biotricity, we're not just transforming remote patient monitoring; we're redefining the very essence of healthcare itself. We are proud to offer award-winning health technology seamlessly integrated with state-of-the-art software. With over 100,000 patients placing their trust in us to improve their long-term cardiac health, we have solidified our position as a trusted healthcare partner. Biotricity's remote patient monitoring devices are designed to optimize patient and healthcare provider workflows. Our goal is to provide critical insights into a patient's health swiftly, resulting in faster treatment and improved outcomes. Our advanced hardware and software solutions enable accurate identification of cardiac problems as they occur, transforming the landscape of care for clinics and patients alike. Physicians can now access real-time data with reports in days, not weeks, while patients wear user-friendly, discreet monitoring devices, offering peace of mind throughout the process. At Biotricity, we firmly believe that the future of healthcare lies in connected medical devices that generate data leveraged by both physicians and individuals. We envision a healthcare ecosystem where these devices seamlessly integrate with big data, predictive AI, and machine intelligence, ushering in an era of better and faster analytics for superior care delivery. Join us as we continue to lead the way in digital health innovation, pioneering advancements that are not just transforming healthcare but also enhancing lives. Together, we are creating a healthier and more connected future. Biotricity's stock is trading under the ticker, “BTCY”.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Imperative Care is a Silicon Valley-based medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Follow Imperative Care Stroke, Imperative Care Vascular, Telos Health and Kandu Health for product and business-level updates.

Karuna Labs, founded in 2016 and based in San Francisco, California, is a digital therapeutics company focused on non-invasive solutions for chronic pain management. The company has secured $3 million in funding from investors such as Anorak Ventures, Baseline Ventures, and DreamIt Ventures. Karuna Labs offers **KarunaHOME**, a 12-week at-home program that combines proprietary neurotechnology with personalized behavioral coaching. The program features the **Karuna Virtual Embodiment Training™ (KVET™)** system, which uses virtual reality technology to provide visual feedback during rehabilitation. Patients receive one-on-one support from trained pain coaches, focusing on sensory reprocessing and cognitive behavioral therapy to help retrain neural pathways associated with chronic pain. The program is designed to be non-pharmacological, flexible, and evidence-based, addressing conditions like low back pain, shoulder pain, and neuropathic pain. Karuna Labs also partners with healthcare providers to integrate its program into clinical workflows, enhancing functional rehabilitation and return-to-work outcomes.

We're developing digital treatments for people living with chronic health conditions.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

OptraHEALTH® is at the forefront of healthcare innovation, leveraging cutting-edge Artificial Intelligence to transform patient care and streamline operations for providers and payors alike. At the heart of this revolution is our flagship AI platform, HealthFAX™. HealthFAX™ isn't just another healthcare tool—it's a comprehensive AI ecosystem designed to redefine the entire patient journey. From the moment a patient considers seeking care to long after their visit, HealthFAX™ is there, invisibly orchestrating a seamless, efficient, and patient-centric experience. Imagine a healthcare world where: * Digital front doors welcome patients with personalized, AI-driven guidance * Intake processes are streamlined, reducing wait times and frustration * Intelligent triage ensures patients receive the right care at the right time * Accurate cost estimates eliminate billing surprises * AI-powered patient counseling provides round-the-clock support * Insurance information is clarified with ease, reducing administrative burdens But HealthFAX™ doesn't stop there. Post-visit, our AI continues to work tirelessly: * Automating report analysis for faster, more accurate diagnoses * Managing follow-ups to ensure no patient falls through the cracks * Providing actionable insights to continuously improve care quality In the age of value-based care and the No Surprises Act, HealthFAX™ is more than a technological advancement—it's a strategic imperative. By automating complex processes, ensuring regulatory compliance, and enhancing communication at every touchpoint, HealthFAX™ allows healthcare organizations to focus on what truly matters: delivering exceptional patient care. Join the AI-driven healthcare revolution with OptraHEALTH®. Together, we're not just improving healthcare—we're reimagining it.

StrokeDx provides portable, rapid, and non-invasive stroke diagnostic and imaging tools.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics' near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.

XP Health is a digital-first vision platform focused on eye exams and eyewear that uses customer-centric design and technology to be more affordable, accessible, and provide a better member experience. XP Health was founded to combat the often confusing, expensive, and frustrating experiences common with vision insurance. The company was named to Fast Company’s list of “The World's Most Innovative Companies,” and in 2022 expanded from 30 to 1500+ customers.